Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
Neoadjuvant chemotherapy followed by interval debulking surgery in patients with serous endometrial cancer with transperitoneal spread (stage IV): a new preferred treatment?
British Journal of Cancer, 07/02/09
Vandenput I et al. - In a study to investigate the value of neoadjuvant chemotherapy (NACT), followed by interval debulking surgery (IDS), in endometrial cancer with transperitoneal spread (stage IV), it was found that use of NACT resulted in a high rate (80%) of optimal IDS for treatment of endometrial cancer with transperitoneal spread.
Methods- Pts with endometrial cancer with transperitoneal spread, as determined by laparoscopy (±pleural effusion), were treated with NACT.
- Efficacy was determined according to the Response Evaluation Criteria in Solid Tumors (RECIST), residual tumour at IDS and histopathological assessment of tumour regression.
- 30 pts (median age: 65 yrs) received 3–4 cycles of NACT (83% paclitaxel/carboplatin).
- Histopathological subtypes were as follows: serous (90%), clear cell (3%), and endometrioid (6%) carcinoma.
- Response according to RECIST was as follows: 2 (7%) complete remission, 20 (67%) partial remission, 6 (20%) stable disease, and 2 (7%) progressive disease (PD).
- Pts with PD were not operated upon.
- 24 pts (80%) had optimal cytoreduction (R 1 cm), of whom 22 (92%) were without residual tumour.
- 4 pts were considered inoperable and were excluded from further analysis.
- Median progression-free survival (PFS) and overall survival (OS) times were 13 and 23 mos, respectively.
- Histopathological features of chemoresponse in both uterus and omentum were related to better PFS and OS.
- Absence of tumour infiltration and necrosis were associated with prognosis.
Today in Gynecologic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Potential predictive markers of chemotherapy resistance in stage III ovarian serous carcinomas
BMC Cancer, 10/21/09
Adjuvant radiotherapy and chemoradiation after surgery for cervical cancer
Cochrane Reviews, 10/09/09
Cost-Effectiveness of Human Papillomavirus Vaccination and Cervical Cancer Screening in Women Older Than 30 Years in the United States
Annals of Internal Medicine, 10/20/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Nonsteroidal anti-inflammatory drugs
Cancer, 10/16/09
Docetaxel versus docetaxel alternating with gemcitabine as treatments of advanced breast cancer: final analysis of a randomised trial
Annals of Oncology, 10/13/09
Lymphoma in patients treated with anti-TNF. Results of the 3-year prospective French RATIO registry.
Annals of Rheumatic Diseases, 10/22/09
Sponsor
Article Search
Sponsor
Sponsor


See Latest Articles


